Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Idorsia Pharmaceuticals Ltd. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 examiners across 5 art units, showing broad examiner distribution with some concentration at the art-unit level.
KOSACK, JOSEPH R is the busiest examiner, with 1 pending action. The portfolio therefore calls for separate examiner-specific responses, supported by centralized review of recurring pharmaceutical claim and disclosure issues.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (60%) |
| Double-patenting only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSACK, JOSEPH R | 1 | 74.8% | -6.1% |
| SEUDIEU SEUDIEU, CARINE PATRICIA | 1 | — | — |
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
| STOCKTON, LAURA LYNNE | 1 | 75.3% | +33.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18868080 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | SEUDIEU SEUDIEU, CARINE PATRICIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548833 | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | CHO, DAVID H | 9d |
| 17773216 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | STOCKTON, LAURA LYNNE | 77d |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 3991 | 1 |
| 1623 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18868772 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | KOSACK, JOSEPH R | 3991 | §112 | Non-Final OA | — | Pending | Nov 24, 2024 |
| 18868080 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | SEUDIEU SEUDIEU, CARINE PATRICIA | 1626 | §103§112Other | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18705346 | CCR6 RECEPTOR MODULATORS | BAUER, BRIANNA LEE | 1623 | §112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18548833 | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | CHO, DAVID H | 1693 | DP | Final Rejection | 9d | Pending | Sep 01, 2023 |
| 17773216 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | STOCKTON, LAURA LYNNE | 1626 | §112 | Final Rejection | 77d | Pending | Aug 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIdorsia Pharmaceuticals Ltd. has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Joseph R Kosack has the most, with 1 of Idorsia Pharmaceuticals Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
